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Abstract: Introduction. As more solid organ transplantations are
performed in patients infected with human immunodeficiency virus
(HIV), post-transplant complications in this population are becoming
better defined.
Methods. Using serum samples from the Solid Organ Transplantation
in HIV: Multi-Site Study, we studied the epidemiology of acquired
hypogammaglobulinemia (HGG) after liver transplantation (LT) in
79 HIV-infected individuals with a median CD4 count at enrollment
of 288 (interquartile range 200–423) cells/lL. Quantitative
immunoglobulin G (IgG) levels before and after LT were measured,
with moderate and severe HGG defined as IgG 350–500 mg/dL and
<350 mg/dL, respectively. Incidence, risk factors, and associated
outcomes of moderate or worse HGG were evaluated using Kaplan–
Meier estimator and proportional hazards (PH) models.
Results. The 1-year cumulative incidence of moderate or worse HGG
was 12% (95% confidence interval [CI]: 6–22%); no new cases were
observed between years 1 and 2. In a multivariate PH model, higher
pre-transplant model for end-stage liver disease score (P = 0.04) and
treated acute rejection (P = 0.04) were both identified as significant
predictors of moderate or worse HGG. There was a strong
association of IgG levels <500 mg/dL with non-opportunistic serious
infection (hazard ratio [95% CI]: 3.5 [1.1–10.6]; P = 0.03) and
mortality (3.2 [1.1–9.4]; P = 0.04). These associations held after
adjustment for important determinants of infection and survival
among the entire cohort.
Conclusion. These results suggest that a proportion of HIV-positive
LT recipients will develop clinically significant HGG after
transplantation.
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Since the introduction of highly active antiretroviral
therapy (HAART) in 1996, the life expectancy of human
immunodeficiency virus (HIV)-infected individuals in
developed countries has increased greatly (1). In large
part, because of this improved survival, HIV is no
longer considered a contraindication to solid organ
transplantation (SOT) (2). In this developing area of
transplantation, the nature and outcomes of common
post-transplant complications in HIV-infected individu-
als are still being defined.
One of these complications is acquired hypogamma-
globulinemia (HGG), a well-described phenomenon
after SOT (2). Patients require lifelong anti-rejection
therapy after SOT, and many of the therapies used to
achieve this have direct or indirect effects on humoral
immune function. Reports in thoracic and abdominal
organ transplantation have shown that a significant
minority of recipients will develop clinically significant
low immunoglobulin levels after SOT, and that this
condition may predispose these subjects to adverse
outcomes. In a cohort of 111 heart transplant recipients,
10% had immunoglobulin G (IgG) levels <350 mg/dL
after transplantation and were found to have a signif-
icantly increased risk of opportunistic infection
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compared with patients with higher IgG levels (3).
Similarly, a single-center study of lung transplant
recipients found IgG levels of <400 mg/dL in 37% of
recipients tested; affected subjects had an increased
risk of bacterial, fungal, and tissue-invasive cytomega-
lovirus (CMV) disease compared with patients with IgG
levels >600 mg/dL (4). More recently, a cohort of
kidney transplant recipients was found to have higher
risk of bacteremia and acute pyelonephritis, if they
developed HGG within 6 months of transplantation (5).
Recently, enrollment for the SOT in HIV: Multi-Site
Study was completed. This study, which includes >250
patients, is investigating the safety and efficacy liver
transplantation (LT) and kidney transplantation in HIV-
infected persons with end-stage liver and/or kidney
disease. Using stored serum and data from this study,
we evaluated the incidence and associated adverse
outcomes of HGG after SOT in this population and
identified risk factors for development of this condition.
Materials and methods
We conducted a post-hoc analysis of prospectively
collected serum samples and clinical data from the
SOT in HIV: Multi-Site Study, which included 125 HIV-
infected patients undergoing LT between October 2003
and February 2010 and was performed under the
ClinicalTrials.gov number NCT00074386. For this
study, institutional review board approval was granted
by the University of Chicago Medical Center, Chicago,
Illinois, USA (IRB: 10-477-A). The full inclusion and
exclusion criteria have been previously published (6).
Briefly, patients seeking LT needed to have a CD4+
T-cell count of >100 cells/lL for 6 months and an
undetectable viral load on a stable HAART regimen for
3 months prior to transplantation. Patients with a
history of acquired immunodeficiency syndrome
(AIDS)-defining opportunistic infections were excluded
before April 2002. After that time, patients with treated
opportunistic infections other than progressive multi-
focal leukoencephalopathy, chronic cryptosporidiosis,
lymphoma, and visceral Kaposi’s sarcoma were eligible
for inclusion. Induction immunosuppression was not
required but could be used at the discretion of the
transplant team. All patients initially received cortico-
steroids and a calcineurin inhibitor (cyclosporine or
tacrolimus) with or without mycophenolate mofetil. For
opportunistic infection prevention, LT recipients
received lifelong Pneumocystis jirovecii pneumonia pro-
phylaxis with trimethoprim-sulfamethoxazole, dapsone,
or atovaquone, and brief antifungal prophylaxis with
fluconazole. Valganciclovir was given as secondary
prophylaxis against CMV reactivation for 1 month after
transplantation.
Design
Serum samples stored at 80°C were used to conduct
this study. Time point samples used in the analysis
included the following: time 0 (pre-transplant),
3 months, 6 months, 1 year, and 2 years post trans-
plant. Patients were excluded from analysis if no pre-
transplant or no post-transplant serum sample was
available for analysis, or if they had preexisting HGG.
Measurements
Quantitative IgG levels were performed at the Univer-
sity of Chicago Medical Center core clinical laboratory.
Samples were assayed using the Roche IgG-s Tina-
quant platform (Roche Diagnostics, Indianapolis,
Indiana, USA). HGG was defined as “moderate” if the
IgG level was 350–500 mg/dL and “severe” if the IgG
level was <350 mg/dL. These values have been sug-
gested in previous publications and are similar to levels
used by other studies (2, 4, 7).
The primary study database was utilized to investi-
gate the clinical and demographic risk factors for the
development of HGG. Variables analyzed included the
following: age, race, gender, body mass index (BMI) at
enrollment (<21), pre-transplant BMI (<21), detectable
HIV RNA at enrollment, CD4 count and nadir CD4
count at enrollment, hepatitis C virus (HCV) infection
status, combined kidney–liver transplant, pre-trans-
plant model for end-stage liver disease (MELD) score,
donor age (by decade), basiliximab/daclizumab induc-
tion, initial tacrolimus therapy (vs. cyclosporine),
mycophenolate mofetil administration, HAART regi-
men, ganciclovir/valganciclovir use, and receipt of
hepatitis B immunoglobulin within 1 week of trans-
plant. Baseline IgG level, as measured from the time 0
(pre-transplant) serum samples, was also included in
this analysis. Post-transplant CD4 count and treated
acute rejection (AR) were examined as time-dependent
covariates.
Adverse events associated with HGG were also
analyzed with the existing database and included all-
cause mortality, treated AR, and non-opportunistic
serious infection in this analysis. Non-opportunistic
serious infection was defined as an infection occurring
during hospitalization or requiring hospitalization for
treatment. Opportunistic serious infections were not
included as there were too few (2 cases of esophageal
582 Transplant Infectious Disease 2013: 15: 581–587
Gregg et al: Low IgG in HIV+ liver transplant recipients
candidiasis and 1 case of pneumocystosis) to perform
any meaningful analysis.
Statistical analysis
Cumulative incidence of moderate or worse HGG was
calculated with the Kaplan–Meier method, and 95%
confidence interval (CI) was estimated with the Green-
wood’s formula. Moderate or worse HGG was evalu-
ated as a time-varying covariate in proportional hazards
(PH) models for death, treated AR, and non-opportu-
nistic serious infection. Risk factors for moderate or
worse HGG were evaluated via PH models as well. All
variables with P < 0.15 from the univariate model were
included in an initial multivariate model. Subsequently,
variables with P > 0.1 were excluded, the model was
refit, and all interactions examined. A 2-sided P-value
of <0.05 was considered to indicate statistical signifi-
cance. Statistical analyses were performed with SAS




Of the 125 patients who underwent LT in the SOT in
HIV: Multi-Site Study, 9 subjects had graft loss before
3 months and were excluded from analysis. Of the
remaining 116 subjects, 81 had a pre-transplant and at
least 1 post-transplant IgG level recorded. Two patients
had pre-existing moderate HGG and were also
excluded from analysis. Therefore, 79 LT recipients
(including 4 liver–kidney recipients) were included in
the analysis. Recipients were followed for a median
of 3.0 (interquartile range [IQR] 2.0–4.5) years after
transplant. Baseline demographic data of the included
subjects were analyzed; 20% were women, and 72%
were white. Sixty-five percent developed end-stage
liver disease because of HCV infection. Thirteen
percent had a history of AIDS-related opportunistic
infections or neoplasms. Subjects’ HIV risk categories
were men having sex with men (42%), intravenous
drug users (33%), transfusion (9%), heterosexual
transmission (8%), and unknown (9%). Median baseline
IgG was 1619 (IQR 1184–2267) mg/dL (Fig. 1). The
median age at transplant was 48 (IQR 43–52) years,
median pre-transplant MELD score was 18 (IQR
13–30), and median CD4 count at enrollment was 288
(IQR 200–423) cells/lL. Fifty-two percent received
tacrolimus (vs. cyclosporine) as their initial calcineurin
inhibitor after transplant, and 29% received hepatitis B
immunoglobulin within the first week after transplant
because of hepatitis B co-infection. Fifty-four percent
was on a protease inhibitor (PI)-based regimen shortly
after transplant. Median donor risk index was 1.33
(IQR 1.16–1.63). Ninety-two percent of recipients were
CMV seropositive and/or received an organ from a
CMV-seropositive donor.
Incidence of HGG
Within 12 months of LT, 8 of 79 (10.1%) recipients
developed moderate HGG. No cases of severe HGG
occurred in the same time period. No new cases of
moderate or worse HGG were identified between years
1 and 2 post LT. Kaplan–Meier estimates for cumulative
incidence of HGG at the data collection time points are
shown in Table 1.
Fig. 1. Distribution of immunoglobulin G (IgG) levels pre-transplant
and at select time points post liver transplant (LT).
Kaplan–Meier estimates of cumulative incidence of
hypogammaglobulinemia (IgG <500 mg/dL) after liver transplantation
Time point (post transplant) Kaplan–Meier estimate (95% CI)
3 months 5% (2, 13)
6 months 10% (5, 20)
1 year 12% (6, 22)
2 years 12% (6, 22)
IgG, immunoglobulin G; CI, confidence interval.
Table 1
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Outcomes associated with HGG
The outcomes of interest in our study included mortal-
ity, non-opportunistic serious infection, and treated AR.
Twenty-one subjects died post transplant: 7 before year
1, 10 between years 1 and 3, and 4 beyond year 3.
Reported causes of death were recurrent hepatitis C (in
5), malignancy (in 3), rejection (in 3), infection (in 2),
multisystem organ failure (in 2), cardiac-related (in 2),
and other/unknown (in 4). Of the 79 subjects, 42
developed a non-opportunistic serious infection. The
first non-opportunistic serious infection post transplant
was bacterial for 26 cases, fungal for 4 cases, viral for 4
cases, and of unknown source (no cultures or negative
cultures) for 8 cases. The etiologic agents were
Clostridium difficile (in 6), Enterococcus species (in 5),
Staphylococcus aureus (in 4), Escherichia coli (in 3),
Klebsiella species (in 3), Pseudomonas aeruginosa (in 2),
Staphylococcus epidermidis (in 2), herpes zoster (in 2),
and 1 each of Streptococcus species, Candida albicans,
Torulopsis glabrata, Aspergillus fumigatus, Aspergillus
species, CMV, and other virus. Overall, 29 subjects
experienced treated AR: 27 first episodes were reported
to be acute cellular rejection and 2 to be both acute
cellular and acute vascular rejection.
In univariate analysis, moderate or worse HGG was
associated both with non-opportunistic serious infec-
tion and death, but was not associated with treated AR
(Table 2). Multivariate analysis included adjustment for
important predictors of these outcomes including
combined kidney–liver transplant, pre-transplant BMI
<21, donor age (by decade), HCV infection, and post-
transplant MELD score (time-varying covariate; serious
infection model only). In this analysis, moderate or
worse HGG continued to be significantly associated
with non-opportunistic serious infection (hazard ratio
[HR] 5.2 [95% CI: 1.7–16.4]; P = 0.004) and death
(HR 3.2 [95% CI: 1.1–9.7]; P = 0.04).
Risk factors for HGG
Table 3 shows the univariate and multivariate analysis
of selected predictors for the development of moderate
or worse HGG. Age, baseline IgG level, pre-transplant
MELD score, and treated AR were the only factors with
P < 0.15 from univariate analysis. In the final multivar-
iate model, higher pre-transplant MELD score
(P = 0.04) and treated AR (P = 0.04) were significantly
associated with an increased risk of acquired HGG post
LT, whereas older age was marginally associated with
an increased risk of HGG (P = 0.06). Median pre-LT
MELD score was 29 (IQR 19–38) in subjects with
post-LT HGG and 18 (IQR 13–27) in those without.
Discussion
This is the first report, to our knowledge, of HGG after
SOT in HIV-infected subjects. In this study, we found a
12% cumulative incidence of moderate or worse HGG at
1 and 2 years after LT among HIV-positive recipients.
Patients who developed moderate or worse HGG were
also found to have an increased risk of mortality and
development of non-opportunistic serious infection.
The only previous study evaluating HGG and asso-
ciated outcomes in LT recipients, to our knowledge,
was performed in HIV-negative patients (7). In that
study, 29 of 112 (26%) patients developed IgG levels
<560 mg/dL within 32 weeks of LT; however, almost
half of those patients had preexisting low IgG levels
before transplant. The patients with HGG after trans-
plant did not have any increased risk of infection or
rejection compared with those with IgG levels
>560 mg/dL, but they did have a significantly
increased mortality at both 1 and 5 years. The only
risk factors identified for developing HGG in this study
were preexisting non-A/non-B hepatitis and “rare
causes of hepatitis.”
Our study found moderate HGG after LT in 8 of 79
HIV-infected patients for a cumulative incidence of 12%
at 1 year post LT. This incidence is somewhat less than
those found in previous studies involving non-HIV-
infected heart, lung, and kidney transplant recipients,
Association of moderate or worse hypogammaglobulinemia with
adverse outcomes of infection, rejection, and death
Adverse outcome
Univariate analysis
HR (95% CI, P-value)
Multivariate analysis1

















1Adjusted for significant predictors of serious non-opportunistic
infection (post-transplant MELD score (time-varying), pre-transplant
BMI, hepatitis C infection), and death (combined kidney–liver
transplant, donor age, pre-transplant BMI, hepatitis C infection)
among the entire cohort.
HR, hazard ratio; CI, confident interval; MELD, model for end-stage
liver disease; N/A, not applicable; BMI, body mass index.
Table 2
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where incidences have ranged from 26% to 45% (3, 8, 9).
However, it is similar to the 13% incidence previously
reported in HIV-negative LT recipients without preex-
isting HGG. Several explanations are possible for the
lower incidence in this study, compared with those
seen in previous studies. One explanation is the high
median baseline IgG level of 1619 mg/dL in this
cohort. It is reasonable to expect that an individual
with a higher baseline IgG level may also have higher
post-transplant IgG levels. Among previous SOT stud-
ies examining HGG, published baseline IgG levels have
ranged from 1137 to 1281 mg/dL (3, 8–10). In our
cohort, liver disease and HIV both may have contrib-
uted to the high median pre-transplant IgG concentra-
tion. Hypergammaglobulinemia is well known to occur
in many forms of chronic liver disease. Several mech-
anisms have been proposed as to why this occurs,
including increased immune response to bacterial
antigens from shunted portal blood flow and decreased
catabolism of immunoglobulins by the liver (11, 12).
Additionally, HIV infection frequently leads to poly-
clonal gammopathy with elevated IgG serum levels,
which is thought possibly to be caused by a reduced
number of memory B cells with concomitant hyperac-
tivity of na€ıve B cells (13).
Another possible explanation for the low incidence of
HGG in this study was the option for transplant teams
to forego induction immunosuppression at the time of
transplant. While it might be expected that patients
receiving more intense immunosuppression would be
at higher risk for developing HGG, basiliximab or
daclizumab induction was not found to be a significant
risk factor for HGG in this study.
The most striking findings in our study were the
significant associations of HGG with mortality and non-
opportunistic serious infection. These associations
remained present even when adjusted for important
predictors of survival and infection among the entire
cohort (14). This association with mortality is notable,
as it has now been found in both studies examining
HGG in LT recipients (7). The association of HGG and
non-opportunistic serious infection raises a question as
to the functionality of the IgG present in these patients.
The IgG resulting from HIV gammopathy is composed
of polyspecific self-reactive autoantibodies and non-
specific IgG (13); the increased rate of infection seen in
these patients may indicate that they are deficient in
antigen-specific antibody that contributes to infection
prevention and clearance.
Pre-transplant MELD score and treated AR were the
only clinical risk factors found to be associated with the
development of HGG. Intensified immune suppression
from anti-rejection treatment may likely be responsible
for the low IgG state in these patients, and in fact, this
association has been found previously in heart trans-
plant recipients (3). It is not clear why a higher MELD
score would predispose to developing HGG. Given that
patients with advanced liver disease often have hyper-
gammaglobulinemia, it might be expected that these
patients would be at lower risk for HGG after trans-
plantation. However, individuals with high MELD
scores may have other clinical risk factors not captured
Analysis of possible risk factors for the development of moderate or
worse hypogammaglobulinemia
Univariate predictor HR (95% CI) P-value
Age (by decade) 1.8 (0.9, 3.9) 0.12
Gender (female) 0.6 (0.1, 5.3) 0.69
Race (white) 1.1 (0.2, 5.5) 0.90
BMI at enrollment <21 1.1 (0.1, 9.1) 0.92
Pre-transplant BMI <21 0.9 (0.1, 7.0) 0.88
CD4 at enrollment (per 50 cells/lL) 1.1 (0.96, 1.2) 0.19
Nadir CD4 at enrollment
(per 50 cells/lL)
1.0 (0.8, 1.2) 0.94
Detectable HIV RNA at enrollment 2.1 (0.4, 10.4) 0.36
HCV infection status (positive) 0.9 (0.2, 3.8) 0.89
Combined kidney–liver transplant 3.5 (0.4, 28.5) 0.24
Donor age (by decade) 1.0 (0.6, 1.6) 0.92
PI-based regimen as initial HAART 2.7 (0.5, 13.2) 0.23
Tacrolimus as initial IS
(vs. cyclosporine)
0.7 (0.2, 3.1) 0.63
Initial mycophenolate mofetil use 2.4 (0.3–19) 0.42
HBIg Induction 1.5 (0.4, 6.2) 0.60
Basiliximab/daclizumab induction 1.2 (0.2, 10.2) 0.84
Initial val/ganciclovir use 1.2 (0.1, 9.7) 0.87
Baseline IgG level (log-scale) 0.1 (0.002, 2.0) 0.12
Pre-transplant MELD score 1.06 (1.002, 1.13) 0.04
CD4 count1 (per 50 cells/lL) 0.9 (0.8, 1.2) 0.66
Treated acute rejection1 3.7 (0.9, 15) 0.06
Multivariate predictors
Pre-transplant MELD score 1.08 (1.01, 1.17) 0.04
Treated acute rejection1 4.5 (1.1, 19) 0.04
Age (by decade) 2.0 (0.97, 4.1) 0.06
1Time-varying covariate.
HR, hazard ratio; CI, confidence interval; BMI, body mass index; HIV,
human immunodeficiency virus; HCV, hepatitis C virus; PI, protease
inhibitor; HAART, highly active antiretroviral therapy; IS, immuno-
suppression; HBIg, hepatitis B immunoglobulin; IgG, immunoglobulin
G; MELD, model for end-stage liver disease.
Table 3
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in this study that increase the risk for HGG, such as
protein-losing conditions that might predispose to HGG
(15).
Similarly, owing to the small number of events and
therefore limited power, other important risk factors
might not have been detected with the current data. In
particular, patients who develop HGG may have a
genetic predisposition for this condition. Previous
research has shown that genetic polymorphisms con-
tribute to the pharmacokinetics and pharmacodynam-
ics of common post-transplant immunosuppressant
therapies such as mycophenolate mofetil and tacroli-
mus, suggesting that the degree of immune suppres-
sion may differ between patients receiving maintenance
immunotherapy (16, 17). Further research involving
gene- or micro-arrays would be necessary to further
investigate this possibility.
Our study has several limitations. Overall, 35 of 114
patients were excluded from analysis because of lack of
specimens, although no significant differences existed
between excluded and included patients in baseline
characteristics and post-transplant outcomes. Exclud-
ing these patients may have limited our ability to detect
potential clinical and demographic predictors for devel-
oping HGG after transplant. In addition, the data from
this study cannot elucidate causality. HGG may be a
marker for overall degree of immunosuppression,
thereby making adverse outcomes such as infection
and death more likely, without actually contributing to
either outcome.
In conclusion, our study provides the first evaluation,
to our knowledge, of acquired HGG after LT in HIV-
positive individuals. HIV-positive LT recipients without
preexisting HGG have a similar incidence of develop-
ment of HGG after transplant as do HIV-negative
recipients, and appear to be most at risk within the first
12 months after transplant. These results are encour-
aging, as they do not suggest any additional risk for
HGG in HIV-positive patients undergoing SOT, when
compared with other recipient populations historically.
However, recipients that do develop HGG appear to be
at significantly greater risk of non-opportunistic serious
infection and mortality than those who maintain ade-
quate IgG levels. As high MELD score and treated AR
appear to be risk factors for the development of HGG,
these patients may be a population that should receive
IgG level monitoring to detect HGG early, for possible
treatment with supplemental immunoglobulins. Future
prospective studies should investigate whether admin-
istration of intravenous or subcutaneous immunoglob-
ulin in this population offers protection from the
increased risk of infection and death in patients with
an IgG measurement <500 mg/dL.
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